Investing.com – Madrigal Pharma (NASDAQ: ) missed Q3 analyst estimates. Revenue remains at the same level as forecasted. According to reports on Monday
Madrigal Pharma’s earnings per share (EPS) was $-5.34 on revenue of $0.00. Analyst consensus compiled by Investing.com Expectations for the upcoming release: Previously, the figure was $-4.90 per share based on $0 earnings.
Shares of Madrigal Pharma fell 0.54% to $146.09.
Apart from Madrigal Pharma, there are other companies too. Markets report this month’s earnings in the healthcare sector of the NASDAQ Stock Exchange
Eli Lilly previously estimated Q3 earnings at $0.1 per share on revenue of $9.5B, and $-0.2 on revenue of $8.97B.
Meanwhile, UnitedHealth’s most recently reported performance beat analyst forecasts. Q3 earnings were $6.56 per share on revenue of $92.4B, beating analyst estimates for 2020. Investing.com expects earnings per share to be around $6.33 based on revenue of $91.42B.
Follow the latest developments in company profits with the Investing.com Earnings Calendar
“Avid gamer. Social media geek. Proud troublemaker. Thinker. Travel fan. Problem solver.”